A single infusion of a gene-editing therapy has all but shut off the disabling, sometimes life-threatening swelling attacks that define a rare genetic disorder, and it did so by rewriting a faulty gene inside patients’ bodies rather than in a laboratory dish. In a late-stage trial, the one-time treatment cut attacks by the vast majority and left most patients free of them entirely, a result its developers describe as a functional cure. Just as important as the numbers is the method: the therapy is delivered straight into the bloodstream and does its editing inside the body, a first for a CRISPR medicine reaching this stage.
Editing the KLKB1 gene inside the body
The treatment, known as lonvo-z, targets hereditary angioedema, an inherited condition in which patients suffer unpredictable episodes of severe swelling in the face, throat, abdomen and limbs. Attacks involving the airway can be fatal, and patients typically manage the disease with lifelong preventive drugs taken on a regular schedule. Lonvo-z takes a fundamentally different approach. As an account of the breakthrough explains, the therapy uses CRISPR gene editing to permanently switch off a gene called KLKB1, which drives the runaway biochemical cascade that produces the swelling. Knock out that gene, and the body stops making the protein that sets attacks in motion.
The elegance is in the durability. Because the edit alters the relevant cells directly, a single dose is designed to deliver a lasting effect rather than the ongoing suppression that daily or twice-weekly medicines provide.
An 87% drop in attacks from one dose
The trial results were striking. According to the developer’s report on the late-stage study, a single infusion of lonvo-z reduced swelling attacks by 87 percent compared with placebo over the six-month evaluation period, meeting the trial’s primary goal. Even more telling for patients, a majority, 62 percent, were completely free of attacks during that window. For a disease measured by the frequency and severity of unpredictable, frightening episodes, driving attacks to zero for most participants represents a dramatic shift from mere management toward something closer to resolution.
Those figures cleared not only the study’s main endpoint but its secondary measures as well, giving the therapy a broad base of evidence rather than a single favorable readout.
Why “in vivo” editing is the milestone
The scientific significance goes beyond one rare disease. Most gene-editing therapies approved so far work outside the body: doctors remove a patient’s cells, edit them in a lab and infuse the corrected cells back, a complex and costly process suited to blood disorders. Lonvo-z instead performs the edit in vivo, meaning inside the living body, by delivering the CRISPR machinery through an infusion that carries it to the target cells in the liver. As coverage of the results notes, that makes it a landmark for the field, because in-body editing could eventually make gene therapies far simpler to administer and applicable to a much wider range of conditions than the labor-intensive out-of-body approach allows.
If in vivo editing proves safe and durable at scale, it would remove one of the biggest practical barriers that has kept gene editing confined to a handful of specialized centers and severe diseases.
The road to regulators, and what “cure” really means
The developer has moved to translate the data into an approved product. Industry reporting describes the company racing its in vivo CRISPR therapy toward the Food and Drug Administration on the strength of the trial, beginning a rolling submission that could make lonvo-z the first in-body CRISPR medicine to seek regulatory clearance, with a potential commercial launch as early as 2027. That timeline underscores how quickly the field has advanced from proof-of-concept to a treatment knocking on the door of approval.
The word “cure” carries caveats, though. The therapy is not yet approved, and while a single dose delivered striking six-month results, gene editing is permanent by design, so long-term follow-up is essential to confirm the benefit holds for years and to watch for any delayed effects. Regulators will weigh the durability and safety data before deciding, and the irreversibility of editing a person’s DNA raises the bar for that review.
A template for treating disease at its genetic root
Hereditary angioedema is a comparatively small market, but the approach lonvo-z pioneers could ripple far beyond it. The same in vivo editing strategy, delivering CRISPR to switch off or correct a disease-causing gene without ever removing cells from the body, is being explored for other conditions rooted in single genes. A success here would validate a platform that treats disease at its genetic source rather than managing symptoms indefinitely.
For patients who have spent their lives bracing for the next swelling attack and dosing to prevent it, the prospect of a one-time infusion that all but ends the disease is a profound change. And for the broader promise of gene editing, a therapy that works inside the body and heads toward approval marks a turning point in how far the technology has come from the laboratory bench to the clinic.
This article was produced with the assistance of AI and reviewed by the Morning Overview editorial team.
More from Morning Overview
